Braidwell LP Xenon Pharmaceuticals Inc. Transaction History

Braidwell LP

$1.79 Billion
Q4 2024

A detailed history of Braidwell LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Braidwell LP holds 2,913,964 shares of XENE stock, worth $115 Million. This represents 6.4% of its overall portfolio holdings.

Number of Shares

2,913,964

Previous 2,707,255 7.64%

Holding current value

$115 Million

Previous $107 Billion 99.89%

% of portfolio

6.4%

Previous 3.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$38.14 - $45.74 $7.88 Million - $9.45 Million	206,709 Added 7.64%	2,913,964 $114 Million
Q3 2024 Nov 14, 2024	BUY	$36.12 - $43.96 $5.3 Million - $6.45 Million	146,682 Added 5.73%	2,707,255 $107 Billion
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $45.4 Million - $54.8 Million	1,252,562 Added 95.76%	2,560,573 $99.8 Billion
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $14.5 Million - $17 Million	-339,300 Reduced 20.6%	1,308,011 $56.3 Billion
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $13.1 Million - $21.2 Million	-456,085 Reduced 21.68%	1,647,311 $75.9 Billion
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $9.4 Million - $10.9 Million	275,043 Added 15.04%	2,103,396 $71.9 Billion
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $10.8 Million - $13.4 Million	-308,757 Reduced 14.45%	1,828,353 $70.4 Billion
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $19.7 Million - $23.8 Million	589,000 Added 38.05%	2,137,110 $76.5 Billion
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $51.2 Million - $61 Million	1,548,110 New	1,548,110 $61 Billion

Others Institutions Holding XENE

# of Institutions

219

Shares Held

70.4M

Call Options Held

109K

Put Options Held

2.1K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.45B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account